These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 12652371)

  • 21. Current status of HIV infection: a review for non-HIV-treating physicians.
    Knoll B; Lassmann B; Temesgen Z
    Int J Dermatol; 2007 Dec; 46(12):1219-28. PubMed ID: 18173512
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Viral response to antiretroviral therapy in a patient coinfected with HIV type 1 and type 2.
    Rodés B; Toro C; Jiménez V; Soriano V
    Clin Infect Dis; 2005 Jul; 41(2):e19-21. PubMed ID: 15983906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [A short-term trial of Didanosine, stavudine, and nevirapine combination therapy for human immunodeficiency virus infection].
    Zheng YH; Yang X; Chang WH
    Hunan Yi Ke Da Xue Xue Bao; 2003 Aug; 28(4):390. PubMed ID: 14653126
    [No Abstract]   [Full Text] [Related]  

  • 24. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy.
    European Collaborative Study
    Clin Infect Dis; 2005 Feb; 40(3):458-65. PubMed ID: 15668871
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Late diagnosis of HIV infection: major consequences and missed opportunities.
    Fisher M
    Curr Opin Infect Dis; 2008 Feb; 21(1):1-3. PubMed ID: 18192778
    [No Abstract]   [Full Text] [Related]  

  • 26. [Major breakthroughs in the medical treatment].
    Kirk O; Gerstoft J; Lundgren JD; Obel N
    Ugeskr Laeger; 2009 Mar; 171(10):787-9. PubMed ID: 19265601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Social aspects of antiretroviral therapy scale-up: introduction and overview.
    Hirsch JS; Parker RG; Aggleton P
    AIDS; 2007 Oct; 21 Suppl 5():S1-4. PubMed ID: 18090262
    [No Abstract]   [Full Text] [Related]  

  • 28. Effect of highly active antiretroviral therapy on the incidence and clinical manifestations of visceral leishmaniasis in human immunodeficiency virus-infected patients.
    Fernández Cotarelo MJ; Abellán Martínez J; Guerra Vales JM; Martínez Sánchez P; Rodrigo Gómez De La Bárcena M; Salto Fernández E
    Clin Infect Dis; 2003 Oct; 37(7):973-7. PubMed ID: 13130410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV remains a deadly disease.
    Lundgren JD
    HIV Med; 2004 Jul; 5(4):251-2. PubMed ID: 15236612
    [No Abstract]   [Full Text] [Related]  

  • 30. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.
    Sánchez JM; Ramos Amador JT; Fernández de Miguel S; González Tomée MI; Rojo Conejo P; Ferrnado Vivas P; Clemente Vivas J; Ruiz Contreras J; Nogales Espert A
    Pediatr Infect Dis J; 2003 Oct; 22(10):863-7. PubMed ID: 14551485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Antiretroviral therapy in 2004].
    Jablonowski H
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():46-8, 50-1. PubMed ID: 15373049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment acceleration program and the experience of the DREAM program in prevention of mother-to-child transmission of HIV.
    Palombi L; Marazzi MC; Voetberg A; Magid NA
    AIDS; 2007 Jul; 21 Suppl 4():S65-71. PubMed ID: 17620755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of HAART therapy on co-infection of tuberculosis and HIV cases for 9 years in Taiwan.
    Tseng SH; Jiang DD; Hoi HS; Yang SL; Hwang KP
    Am J Trop Med Hyg; 2009 Apr; 80(4):675-7. PubMed ID: 19346398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sarcoidosis in HIV-infected patients in the era of highly active antiretroviral therapy.
    Foulon G; Wislez M; Naccache JM; Blanc FX; Rabbat A; Israël-Biet D; Valeyre D; Mayaud C; Cadranel J
    Clin Infect Dis; 2004 Feb; 38(3):418-25. PubMed ID: 14727215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insulin and carbohydrate dysregulation.
    Gelato MC
    Clin Infect Dis; 2003 Apr; 36(Suppl 2):S91-5. PubMed ID: 12652377
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Similar challenges with retention in care issues.
    Krentz HB; Siemieniuk RA; Gill MJ
    Clin Infect Dis; 2007 Dec; 45(11):1527. PubMed ID: 17990241
    [No Abstract]   [Full Text] [Related]  

  • 37. Recent developments in HIV treatment, Part 2.
    Boyle BA
    AIDS Read; 2005 Jun; 15(6):277-9, 284. PubMed ID: 15962449
    [No Abstract]   [Full Text] [Related]  

  • 38. Resolution of human immunodeficiency virus type 1 infection-related severe pulmonary hypertension in a very low-birth-weight infant.
    Feiterna-Sperling C; Hüseman D; Timme J; Bührer C; Obladen M
    Pediatr Infect Dis J; 2008 Jun; 27(6):564-7. PubMed ID: 18449067
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy.
    Recsky MA; Brumme ZL; Chan KJ; Wynhoven B; Yip B; Dong WW; Heath KV; Montaner JS; Levy AR; Hogg RS; Harrigan PR
    J Infect Dis; 2004 Jul; 190(2):285-92. PubMed ID: 15216463
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiretroviral therapy for HIV-infected people in Papua New Guinea: challenges and opportunities.
    McBride WJ; Bradford D
    P N G Med J; 2004; 47(1-2):22-30. PubMed ID: 16496512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.